Metrix Partners advises Elaia Partners on its €1.3M seed round in Zymvol

Metrix Partners advised Elaia Partners on its €1.3M seed investment in Zymvol in February 2023. It was Zymvol’s first seed funding. Elaia is a European venture capital firm with a strong technology focus.

Elaia Partners seed investment in Zymvol advised by Metrix Partners

About Zymvol

Zymvol is a Barcelona biotech company that designs enzymes for the pharmaceutical, food and chemical industries. Its software platform runs cloud-based computer simulations so that clients can discover and optimise enzymes faster than with laboratory screening alone, as La Vanguardia reported.

Enzymes are biological catalysts. Replacing chemical steps with enzymatic ones can cut energy use, solvents and waste in manufacturing. Zymvol’s mission is to make improved, sustainable enzymes widely used across industries. Before the round, it had built a team of more than 20 people with offices in Barcelona and Boston.

The seed round

Zymvol said it would use the funds to exploit its portfolio of enzymes, create its own products and bring them to market. This marked a shift from a pure service model, designing enzymes for clients, to a model that adds proprietary products.

Metrix Partners’ role for Elaia Partners

Metrix advised Elaia Partners on the investment. For a science-based company moving from services to products, the review covered:

  • Service revenue by client and project, reconciled to the accounts.
  • Margins on research contracts and utilisation of the scientific team.
  • Intellectual property: ownership of designs, client rights and licences.
  • Public grants and loans, with their conditions and repayment schedules.
  • The budget and milestones for developing proprietary products.

Five lessons for investors in computational biotech

  1. Separate services from platform value. Service revenue funds the company but scales with headcount. Investors value the platform and products more.
  2. Check IP ownership. When designs are created for clients, contracts determine who owns them. This affects the product strategy.
  3. Public funding is common. Spanish biotech companies often hold loans from bodies such as ENISA, CDTI or regional agencies. Their terms belong in the analysis.
  4. Validation takes time. Moving from simulation to industrial production requires laboratory and pilot-scale work.
  5. Industrial customers buy slowly. Chemical and pharma companies test new processes carefully. Sales cycles are long.

What biotech founders should prepare for a seed round

  • Monthly accounts reconciled to the statutory filings.
  • Revenue and margin by client and project type.
  • A summary of IP, licences and client contract terms.
  • A list of public funding with amounts, conditions and repayments.
  • A product development plan with budget and milestones.

Why industrial enzymes matter

Manufacturers face pressure to cut emissions and hazardous chemicals. Enzymes work at lower temperatures and in water, and they are highly selective, which reduces by-products. The barrier has been the time and cost of finding an enzyme that performs well enough for an industrial process. Computational design shortens that search by testing thousands of variants in simulation before any laboratory work.

If that approach works at scale, the market reaches well beyond pharma, into food processing, detergents, textiles and plastics recycling. That breadth is part of what attracts technology-focused investors to the sector.

Metrix Partners and Elaia Partners

Metrix also advised Elaia Partners on its €2.5M seed investment in Qbeast. Zymvol later joined the Metrix client list and obtained a €700,000 participative loan from Avançsa.